Crystal Pharmatech

About Crystal Pharmatech

Crystal Pharmatech Inc. : What we do:

•             Vetting of API forms and formulations for First-in-Human studies

•             maintain the integrity of downstream processes.

•        &nbs...

  • US
  • 2018
    On CPHI since
  • 1
  • 50 - 99
Company types
Contract Service
Contact info

Products from Crystal Pharmatech (3)

  • Solid Form Screening

    Product Solid Form Screening

    We know that the needs in early development are different from the needs in late development and we tailor our screening approach based on information from the client and our experience with a wide range of compounds. At Crystal Pharmatech, we utilize a unique screening approach that co...
  • Chiral Separation by Crystallization

    Product Chiral Separation by Crystallization

    More than 70% of drug candidates worldwide are chiral. Typically, for chiral API, only one enantiomer or diasteromer is biologically active or desirable. Therefore, the production of enantiopure compounds or diastereomers is imperative. In the production of small molecule drugs with desired chirality, sepa...
  • Crystallization

    Product Crystallization

    Crystallization is a critical unit operation in API manufacturing for both final product and intermediates. Desired product quality attributes can be obtained economically with high efficiency through well-designed and controlled crystallization processes.

Crystal Pharmatech Resources (2)

  • News Exploring the Pharmaceutical Solid State by Molecular Simulation

    Abstract:  We explore how state-of-the-art molecular simulation can be used to train advanced neural networks for high-fidelity, high-accuracy forcefields from Density-Functional Simulation. This allows - indeed, liberates and empowers, us - to train more accurate force-fields and apply this to basin-hopping journeys through potential-energy landscapes, allowing us to revolutionise the prediction and validation of polymorph populations.

    Biography:Following a First in Chemical Engineering in 2000 and Ph.D. on crystallisation molecular simulation in 2003 at UCD Chemical Engineering, Niall English carried out further simulation and theoretical studies on hydrates at the National Energy Technology Laboratory, a U.S. DOE research facility. During 2005 to 2007, he worked for the Chemical Computing Group in Cambridge, GB. Here, Niall developed molecular simulation codes, protocols and methods for biomolecular simulation, used chiefly in structure-based drug design applications in the pharmaceutical industry. Niall commenced his position as a lecturer in the School of Chemical and Bioprocess Engineering in January 2007, being promoted to senior lecturer in January 2014 and professor in February 2017. He is currently lecturing on chemical-engineering design, thermodynamics, experimental design, process control and molecular simulation. His research interests encompass nanoscience (such as nano-bubbles), energy and materials - gas hydrates, solar and renewable energies, and simulation of e/m field effects on (nano)materials and biological systems. He has a special interest in water, whether in the bulk or at interfaces or in (nano-)confined systems. He is also co-founder of two campus spin-out companies, BioSimulytics and Aqua-B.

    Chief Technology OfficerBioSimulytics 
  • Video Title: Avoiding Drug Failures: Right First Time; Fast First Time

    Choosing the right form and formulation is a continuously evolving field. To stay at the cutting edge of this field internally and continuously educate the community externally, Crystal Pharmatech has gathered a panel of distinguished scientists from various disciplines to support our “Crystal Clear Pathways to Select API Form and Formulation”.

    The panel serves to educate pharmaceutical companies on the importance of proper selection of API phase and formulation. This panel has combined to assess form and formulation for hundreds of development compounds. Experiencing it all, they've seen the successes and the horror stories of development and are now willing to share them with you through case studies, panel discussions, and webinars.